ÃֽŠÀÇ°úÇÐ Å°¿öµå ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®
8¿ù [ÀÓ»óÀÇÇÐ] ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®
±×¸² 1. ÀÓ»óÀÇÇÐ 8¿ù ÇÙ½É Å°¿öµå ¿¬±¸µ¿Çâ Ŭ¶ó¿ìµå
ÃֽŠÀÇ°úÇÐºÐ¾ß ±¹³»¿Ü Àú³ÎÀ» ÅëÇØ ¹ßÇ¥ÇÑ ÀÓ»óÀÇÇÐ ³í¹®Àº ±¹³» 736Æí°ú ±¹Á¦ Àú³ÎÀ» ÅëÇØ 800ÆíÀÌ ¹ßÇ¥µÇ¾î ÃÑ 1,536ÆíÀÌ ¹ßÇ¥µÇ¾ú´Ù. ÀÌ´Â Àü¿ù 7¿ù¿¡ ºñ±³ÇÏ¿© 16.4% (303Æí)ÀÌ °¨¼ÒÇÑ Ãß¼¼ÀÌ´Ù. ÃֽŠÀÓ»óÀÇÇÐ ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®¿¡¼´Â General Surgery, Neoplasms, Survival Rate, ¹× COVID-19¸¦ Áß½ÉÀ¸·Î ÇÑ ¿¬±¸ÁÖÁ¦¸¦ Áß½ÉÀ¸·Î ¿¬±¸µ¿Çâ ÃàÀ» Çü¼ºÇÏ¿´´Ù. ´ë»óÀÚ ¼ºº°·Î´Â ¿©¼ºÀ» Áß½ÉÀ¸·Î ÇÑ ¿¬±¸°¡ È°¹ßÇÏ°Ô ÁøÇàµÇ°í ÀÖÀ½µµ ³ªÅ¸³µ´Ù(Ç¥ 1).
±×¸² 2. ±¹³» 8¿ù ÀÓ»óÀÇÇÐ ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®
±×¸² 3. ±¹¿Ü 8¿ù ÀÓ»óÀÇÇÐ ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®
Ç¥ 1. ÀÓ»óÀÇÇÐ 8¿ù ÅäÇÈ ³×Æ®¿öÅ© ¸ðµ¨¸µ
Topic1
|
Topic2
|
Topic3
|
Topic4
|
Topic5
|
Risk
|
Women
|
General Surgery
|
Neoplasms
|
COVID-19
|
Sensitivity And Specificity
|
Serum
|
Risk
|
Recurrence
|
Vaccination
|
F-18 Fdg Pet
|
Diabetes
|
Pain
|
Survival Rate
|
Depression
|
Complication
|
Sex
|
Pediatrics
|
Drug Therapy
|
Risk
|
Stroke
|
Bmi
|
Mortality
|
Genes
|
Pediatrics
|
Evaluation Studies As Topic
|
Hypertension
|
Complication
|
General Surgery
|
Brain
|
Women
|
Attention
|
Asthma
|
Neoplasm Metastasis
|
Adolescent
|
General Surgery
|
Risk
|
Population
|
Breast Neoplasms
|
Alzheimer Disease
|
Dataset
|
Learning
|
Chronic Obstructive Lung Disease
|
Liver
|
Older Adults
|
Bone & Bones
|
Balance
|
Risk Factors
|
Risk
|
Women
|
±×¸² 4. 8¿ù ÀÓ»óÀÇÇÐ ÅäÇÈ Å°¿öµå ³×Æ®¿öÅ© ¿¬±¸µ¿Ç⠺м®
Ç¥ 2. 8¿ù ÀÓ»óÀÇÇÐ ¿¬±¸µ¿Çâ »óÀ§ Å°¿öµå (n=1,536)
Å°¿öµå ¼øÀ§
|
±¹³» ÀÓ»óÀÇÇÐ Å°¿öµå
|
±¹¿Ü ÀÓ»óÀÇÇÐ Å°¿öµå
|
ÅëÇÕ ÀÓ»óÀÇÇÐ Å°¿öµå
|
1
|
Risk
|
Risk
|
Risk
|
2
|
General Surgery
|
General Surgery
|
General Surgery
|
3
|
Women
|
Neoplasms
|
Women
|
4
|
Pediatrics
|
Survival Rate
|
Neoplasms
|
5
|
Complication
|
Women
|
Survival Rate
|
6
|
COVID-19
|
COVID-19
|
COVID-19
|
7
|
Neoplasms
|
Brain
|
Complication
|
8
|
Drug
|
Mortality
|
Pediatrics
|
9
|
Recurrence
|
Recurrence
|
Recurrence
|
10
|
Pain
|
Pain
|
Mortality
|
|
Survival Rate
|
|
|
8¿ù¿¡ ¹ßÇ¥µÈ ±¹³»¿Ü ÀÇ°úÇÐºÐ¾ß ³í¹® ¹ßÇ¥ Áß¿¡¼ ÀÓ»óÀÇÇÐ³í¹®ÀÌ Â÷ÁöÇÏ´Â ºñÀ²Àº Àüü¿¡¼ 46.7%¸¦ Â÷ÁöÇÏ¿© Àü¿ù 50.2%¿¡ ºñ±³ÇÏ¿© ¾à°£ °¨¼ÒÇÑ Ãß¼¼¸¦ ³ªÅ¸³»¾úÀ¸³ª, ÀÇ°úÇÐºÐ¾ß Áß¿¡¼ ÀÓ»óÀÇÇÐÀÌ Â÷ÁöÇÏ´Â ºñÀ²Àº Áö¼ÓÀûÀ¸·Î °¡Àå ³ôÀº ¼øÀ§¸¦ ³ªÅ¸³»¾ú´Ù. ÃֽŠÀÓ»óÀÇÇÐ ¿¬±¸µ¿Ç⠺м®¿¡ »ç¿ëµÈ ³í¹® µ¥ÀÌÅÍ´Â ±¹³» Àú³Î°ú ÇØ¿Ü Àú³ÎÀ» ÅëÇØ ¹ßÇ¥µÈ ³í¹® Áß¿¡¼ Çѱ¹ÀÇÇÐ³í¹®µ¥ÀÌÅͺ£À̽º(KMbase)¿Í ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)ÀÇ Æà¸Þµå(PubMed) MEDLINE µ¥ÀÌÅͺ£À̽º¿¡¼ ³í¹®ÀڷḦ ÃßÃâÇÏ¿© ºÐ¼®ÇÏ¿´´Ù.
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC) Á¦°ø
* º» ³»¿ëÀº MedRIC (www.medric.or.kr)ÀÇ ¿¬±¸µ¿Çâ¿¡¼ Á¦°øµÇ´Â ³»¿ëÀÔ´Ï´Ù.